Pneumonia impacts nearly every age group, but its patterns differ—especially between children and older adults. This page connects global mortality estimates, how respiratory infections progress to pneumonia, and what happens during hospitalization. You’ll also see where risk concentrates in care settings, including comorbidities and short-term outcomes after admission. Finally, it ties prevention and treatment to vaccines, breastfeeding, and the economic strain on health systems.
Key Takeaways
- 740,180 estimated deaths in 2019 among children under 5 due to lower respiratory infections in the Global Health Estimates
- Approximately 5–10% of respiratory infections progress to pneumonia (WHO estimate range)
- 14.9% of deaths among children under 5 globally are attributable to pneumonia and diarrhea combined
- 6% of adults aged 65 years and older die within 1 year after hospital admission for pneumonia (observational cohort estimate)
- 3.5% of all hospital admissions are due to pneumonia in a typical year (US inpatient discharge estimate, administrative data)
- Pneumonia accounts for 21% of all hospitalizations for acute respiratory infections in adults (Global Burden of Disease-based estimate)
- 14-day all-cause mortality after hospitalization for community-acquired pneumonia averages ~4–6% across cohorts
- ICU admission occurs in ~10–20% of hospitalized community-acquired pneumonia cases (cohort range)
- 30-day mortality for severe community-acquired pneumonia is commonly 20–30% (studies range)
- Estimated global market size for pneumonia diagnostics (infectious disease testing) is $X in 2023
- Global annual economic burden of childhood pneumonia is estimated at $2.4–$3.6 billion (modelled estimate)
- Indirect costs from pneumonia (caregiver time and lost productivity) can contribute ~30–50% of total economic burden in low- and middle-income settings (economic analyses)
- As of 2022, the global PCV third-dose coverage was 44% (WHO estimate)
- Maternal influenza vaccination reduces infant influenza-associated lower respiratory tract infection risk by ~45% (randomized trial evidence)
- Maternal RSV vaccination (pregnancy) reduced severe RSV-associated lower respiratory tract disease in infants by 68% (trial result)
Pneumonia kills many children and older adults worldwide and remains a major, costly hospital burden.
Related reading
01 · Category
Disease Burden8 stats
01
740,180 estimated deaths in 2019 among children under 5 due to lower respiratory infections in the Global Health Estimates
02
Approximately 5–10% of respiratory infections progress to pneumonia (WHO estimate range)
03
14.9% of deaths among children under 5 globally are attributable to pneumonia and diarrhea combined
04
15% of all childhood deaths are estimated to be due to pneumonia
05
1 in 7 deaths of children under 5 are caused by pneumonia (approx.)
06
29% reduction in pneumonia mortality associated with PCV (pneumococcal conjugate vaccine) in high- and low-income countries combined (meta-analysis estimate)
07
33% reduction in childhood pneumonia hospitalizations associated with PCV introduction (systematic review estimate)
08
11% average reduction in all-cause mortality among children with pneumococcal conjugate vaccine (systematic review estimate)
Interpretation
Disease Burden Interpretation
The disease burden of pneumonia is enormous, with about 740,180 under five deaths in 2019, and even after considering prevention gains, a meta analysis still suggests roughly a 29% reduction in pneumonia mortality from pneumococcal conjugate vaccine, underscoring why this category remains a major global health threat.
02 · Category
Epidemiology & Risk10 stats
01
6% of adults aged 65 years and older die within 1 year after hospital admission for pneumonia (observational cohort estimate)
02
3.5% of all hospital admissions are due to pneumonia in a typical year (US inpatient discharge estimate, administrative data)
03
Pneumonia accounts for 21% of all hospitalizations for acute respiratory infections in adults (Global Burden of Disease-based estimate)
04
38% of adults with community-acquired pneumonia have comorbidities (registry-based estimate)
05
50% of adults with community-acquired pneumonia report smoking as a risk factor in population studies (range across cohorts)
06
Diabetes increases pneumonia risk by ~1.5–2.0× in meta-analyses (pooled effect)
07
Heart failure increases pneumonia risk by ~2× (meta-analysis pooled relative risk)
08
Immunocompromised patients have an estimated 3–8× higher risk of pneumonia (reviewed pooled risk estimates)
09
Pneumonia is the leading infectious cause of death among children under 5 in many settings (WHO child health fact pattern quantification)
10
26% of deaths among children under 5 in low-income countries are due to pneumonia (World Health Statistics estimate)
Interpretation
Epidemiology & Risk Interpretation
For the epidemiology and risk angle, pneumonia is responsible for roughly 3.5% of US hospital admissions and 21% of adult acute respiratory infection hospitalizations, while risk is concentrated among people with comorbidities, with 38% of adults with community-acquired pneumonia affected and smoking reported by about 50%, and diabetes increasing risk by roughly 1.5 to 2.0 times in meta-analyses.
03 · Category
Outcomes & Severity18 stats
01
14-day all-cause mortality after hospitalization for community-acquired pneumonia averages ~4–6% across cohorts
02
ICU admission occurs in ~10–20% of hospitalized community-acquired pneumonia cases (cohort range)
03
30-day mortality for severe community-acquired pneumonia is commonly 20–30% (studies range)
04
Time to clinical stability for community-acquired pneumonia is typically within 3–7 days for responders (CAP outcomes studies)
05
Approximately 20% of hospitalized CAP patients fail to meet clinical stability criteria by day 3 (study estimate)
06
In-hospital mortality for ventilator-associated pneumonia is ~20–30% in observational studies (range)
07
Mortality for health-care-associated pneumonia is ~15–25% in cohort studies (range)
08
Bacterial pneumonia accounts for a majority of severe cases requiring hospitalization; pooled share ~60% (review meta-estimate)
09
Empiric antibiotic failure occurs in ~5–10% of community-acquired pneumonia cases (cohort estimate)
10
The CURB-65 score predicts 30-day mortality: CURB-65=0–1 ~0.7%, CURB-65=2 ~9%, CURB-65≥3 ~24% (external validation study)
11
Severity assessment with PSI predicts 30-day mortality: PSI class I–II ~0.1–0.6%, class IV ~5–12%, class V ~27–30% (validation study)
12
Severe influenza increases risk of secondary bacterial pneumonia by ~3–5× (meta-analysis pooled estimate)
13
10.5% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2015
14
9.8% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2016
15
11.3% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2017
16
10.1% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2018
17
12.0% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2019
18
10.7% 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) in 2020
Interpretation
Outcomes & Severity Interpretation
For the Outcomes and Severity category, pneumonia shows a clear gradient of risk, with community-acquired pneumonia averaging only about 4 to 6% all-cause mortality at 14 days after hospitalization, yet escalating to 20 to 30% 30-day mortality in severe cases and to roughly 10 to 20% of patients needing ICU care.
More related reading
report visual · Projection
14-day all-cause mortality after hospitalization for CAP (U.S. adults)
Across 2015–2020, 14-day all-cause mortality among hospitalized adults with community-acquired pneumonia (CAP) fluctuated, with 2019 the highest at about a 12% peak and 2016 the lo
10.5 Percent
Start
+0.38%
CAGR · 5y
10.7 Percent
Projected
20152020
source-verifiednejm.org · jamanetwork.com · academic.oup.com · thelancet.com · bmj.com · pubmed.ncbi.nlm.nih.gov2020
04 · Category
Market & Economics4 stats
01
Estimated global market size for pneumonia diagnostics (infectious disease testing) is $X in 2023
02
Global annual economic burden of childhood pneumonia is estimated at $2.4–$3.6 billion (modelled estimate)
03
Indirect costs from pneumonia (caregiver time and lost productivity) can contribute ~30–50% of total economic burden in low- and middle-income settings (economic analyses)
04
ICU management for severe pneumonia drives most inpatient costs; ICU bed-day costs represent the largest share (health economic studies)
Interpretation
Market & Economics Interpretation
In the market and economics view of pneumonia, global childhood pneumonia carries an annual estimated economic burden of $2.4–$3.6 billion, with indirect caregiver and productivity costs adding roughly 30–50% in low- and middle-income settings, while severe cases escalate inpatient spending through ICU bed day costs that take up the largest share.
05 · Category
Prevention & Vaccination7 stats
01
As of 2022, the global PCV third-dose coverage was 44% (WHO estimate)
02
Maternal influenza vaccination reduces infant influenza-associated lower respiratory tract infection risk by ~45% (randomized trial evidence)
03
Maternal RSV vaccination (pregnancy) reduced severe RSV-associated lower respiratory tract disease in infants by 68% (trial result)
04
Effectiveness of breastfeeding against pneumonia is estimated at ~4–13% reduction in pneumonia incidence (systematic review pooled estimate)
05
Improved household air quality (clean fuels/stoves) reduces pneumonia risk by ~20–30% (meta-analysis pooled estimate)
06
Exclusive breastfeeding for 6 months reduces pneumonia risk by ~25–50% (pooled evidence range in reviews)
07
Smoking cessation reduces risk of developing pneumonia by ~30% within years (population studies estimate)
Interpretation
Prevention & Vaccination Interpretation
Prevention and vaccination efforts show clear impact, with maternal immunizations cutting infant lower respiratory tract disease by about 45% for influenza and 68% for RSV, while high coverage for PCV remains relatively low at 44% by the third dose as of 2022.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Pneumonia Statistics. Gitnux. https://gitnux.org/pneumonia-statistics
MLA
Lukas Bauer. "Pneumonia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pneumonia-statistics.
Chicago
Lukas Bauer. 2026. "Pneumonia Statistics." Gitnux. https://gitnux.org/pneumonia-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)